FDA Holds Workshop on Microarrays In Regulatory Process: Report Planned | GenomeWeb

Microarrays are wending their way into drug development — witness the recent speaker from Eli Lilly at Affymetrix’s investor day last week who revealed that the pharma giant is using Affy chips in mechanism-of-action studies for drugs. The US Food and Drug Administration, however, has not yet decided how to handle this data in the regulatory process.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.